[en] Growth hormone (GH) is a key modulator of growth and GH over-secretion can lead to gigantism. One form is X-linked acrogigantism (X-LAG), in which infants develop GH-secreting pituitary tumors over-expressing the orphan G-protein coupled receptor, GPR101. The role of GPR101 in GH secretion remains obscure. We studied GPR101 signaling pathways and their effects in HEK293 and rat pituitary GH3 cell lines, human tumors and in transgenic mice with elevated somatotrope Gpr101 expression driven by the rat Ghrhr promoter (GhrhrGpr101). Here, we report that Gpr101 causes elevated GH/prolactin secretion in transgenic GhrhrGpr101 mice but without hyperplasia/tumorigenesis. We show that GPR101 constitutively activates not only Gs, but also Gq/11 and G12/13, which leads to GH secretion but not proliferation. These signatures of GPR101 signaling, notably PKC activation, are also present in human pituitary tumors with high GPR101 expression. These results underline a role for GPR101 in the regulation of somatotrope axis function.
Research Center/Unit :
GIGA Molecular Biology of Diseases - ULiège CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Lui, J. C., Garrison, P. & Baron, J. Regulation of body growth. Curr. Opin. Pediatr. 27, 502–510 (2015).
Buchman, M., Bell, S. & Kopchick, J. J. Growth hormone discovery and structure. Pediatr. Endocrinol. Rev. 16, 2–10 (2018).
Steyn, F. J., Tolle, V., Chen, C. & Epelbaum, J. In Comprehensive Physiology vol. 6, pp. 687–735 (John Wiley & Sons, Inc., 2016).
Beckers, A., Petrossians, P., Hanson, J. & Daly, A. F. The causes and consequences of pituitary gigantism. Nat. Rev. Endocrinol. 14, 705–720 (2018).
Rostomyan, L. et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr. Relat. Cancer 22, 745–757 (2015).
Beckers, A. et al. Paleogenetic study of ancient DNA suggestive of X-linked acrogigantism. Endocr. Relat. Cancer 24, L17–L20 (2017).
Trivellin, G. et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N. Engl. J. Med. 371, 2363–2374 (2014).
Beckers, A. et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr. Relat. Cancer 22, 353–367 (2015).
Iacovazzo, D. et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol. Commun. 4, 56 (2016).
Lee, D. K. et al. Discovery and mapping of ten novel G protein-coupled receptor genes. Gene 275, 83–91 (2001).
Laschet, C., Dupuis, N. & Hanson, J. The G protein-coupled receptors deorphanization landscape. Biochem. Pharmacol. 153, 62–74 (2018).
Bates, B. et al. Characterization of Gpr101 expression and G-protein coupling selectivity. Brain Res. 1087, 1–14 (2006).
Trivellin, G. et al. Characterization of GPR101 transcript structure and expression patterns. J. Mol. Endocrinol. 57, 97–111 (2016).
Mcelvaine, A. T., Korytko, A. I., Kilen, S. M., Cuttler, L. & Mayo, K. E. Pituitary-specific expression and Pit-1 regulation of the rat growth hormone-releasing hormone receptor gene. Mol. Endocrinol. 21, 1969–1983 (2007).
Miller, T. L. The rat growth hormone-releasing hormone receptor gene: structure, regulation, and generation of receptor isoforms with different signaling properties. Endocrinology 140, 4152–4165 (1999).
Møller, N. & Jørgensen, J. O. L. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152–177 (2009).
Yin, Z., Williams-Simons, L., Rawahneh, L., Asa, S. & Kirschner, L. S. Development of a pituitary-specific cre line targeted to the Pit-1 lineage. Genesis 46, 37–42 (2008).
Yeung, C.-M., Chan, C.-B., Leung, P.-S. & Cheng, C. H. K. Cells of the anterior pituitary. Int. J. Biochem. Cell Biol. 38, 1441–1449 (2006).
Andoniadou, C. L. et al. Sox2+ stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential. Cell Stem Cell 13, 433–445 (2013).
Hannon, A. M., Thompson, C. J. & Sherlock, M. Diabetes in patients with acromegaly. Curr. Diab. Rep. 17, 8 (2017).
Cotes, P. M., Reid, E. & Young, F. G. Diabetogenic action of pure anterior pituitary growth hormone. Nature 164, 209–211 (1949).
Gilissen, J. et al. Forskolin-free cAMP assay for Gi-coupled receptors. Biochem. Pharmacol. 98, 381–391 (2015).
Dupuis, N. et al. Activation of the orphan G protein–coupled receptor GPR27 by surrogate ligands promotes β -arrestin 2 recruitment. Mol. Pharmacol. 91, 595–608 (2017).
Alvarez Curto, E. et al. Targeted elimination of G proteins and arrestins defines their specific contributions to both intensity and duration of G protein-coupled receptor signaling. J. Biol. Chem. 291, 27147–27159 (2016).
Stallaert, W. et al. Purinergic receptor transactivation by the β 2 -adrenergic receptor increases intracellular Ca2+ in nonexcitable cells. Mol. Pharmacol. 91, 533–544 (2017).
Grundmann, M. et al. Lack of beta-arrestin signaling in the absence of active G proteins. Nat. Commun. 9, 1–7 (2018).
Trinquet, E. et al. D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal. Biochem. 358, 126–135 (2006).
Inoue, A. et al. TGFα shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 9, 1021–1029 (2012).
Geubelle, P. et al. Identification and pharmacological characterization of succinate receptor agonists. Br. J. Pharmacol. 174, 796–808 (2017).
Tashjian, A. H., Yasumura, Y., Levine, L., Sato, G. H. & Parker, M. L. Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone. Endocrinology 82, 342–352 (1968).
Mayo, K. E., Miller, T. L., DeAlmeida, V., Zheng, J. & Godfrey, P. A. The growth-hormone-releasing hormone receptor: signal transduction, gene expression, and physiological function in growth regulation. Ann. N. Y. Acad. Sci. 805, 184–203 (1996).
Cunha, S. R. & Mayo, K. E. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3′,5′-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology 143, 4570–4582 (2002).
Stojilkovic, S. S., Tabak, J. & Bertram, R. Ion channels and signaling in the pituitary gland. Endocr. Rev. 31, 845–915 (2010).
Wu, D., Clarke, I. J. & Chen, C. The role of protein kinase C in GH secretion induced by GH-releasing factor and GH-releasing peptides in cultured ovine somatotrophs. J. Endocrinol. 154, 219–230 (1997).
Lee, E. J., Duan, W. R., Kotlar, T. & Jameson, J. L. Restoration of growth hormone-releasing hormone (GHRH) responsiveness in pituitary GH3 cells by adenovirus-directed expression of the human GHRH receptor. Endocrinology 142, 414–420 (2001).
Tian, C. et al. Nitric oxide inhibits ghrelin-induced cell proliferation and ERK1/2 activation in GH3 cells. Endocrine 38, 412–416 (2010).
Wise-Oringer, B. K. et al. Familial X-linked acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother. J. Clin. Endocrinol. Metab. 104, 4667–4675 (2019).
Strobl, J. S. & Thomas, M. J. Human growth hormone. Pharmacol. Rev. 46, 1–34 (1994).
Ehrnborg, C., Ellegard, L., Bosaeus, I., Bengtsson, B.-A. & Rosen, T. Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults. Clin. Endocrinol. (Oxf.) 62, 449–457 (2005).
Villalobos, C., Núñez, L., Frawley, L. S., García-Sancho, J. & Sánchez, A. Multi-responsiveness of single anterior pituitary cells to hypothalamic-releasing hormones: a cellular basis for paradoxical secretion. Proc. Natl Acad. Sci. USA 94, 14132–14137 (1997).
Núñez, L., Villalobos, C., Senovilla, L. & García-Sancho, J. Multifunctional cells of mouse anterior pituitary reveal a striking sexual dimorphism. J. Physiol. 549, 835–843 (2003).
Vidal, S., Horvath, E., Kovacs, K., Lloyd, R. V. & Smyth, H. S. Reversible transdifferentiation: interconversion of somatotrophs and lactotrophs in pituitary hyperplasia. Mod. Pathol. 14, 20–28 (2001).
Seuntjens, E., Hauspie, A., Vankelecom, H. & Denef, C. Ontogeny of plurihormonal cells in the anterior pituitary of the mouse, as studied by means of hormone mRNA detection in single cells. J. Neuroendocrinol. 14, 611–619 (2002).
Denef, C., Pals, K., Hauspie, A., Vankelecom, H. & Seuntjens, E. Combinatorial expression of phenotypes of different cell lineages in the rat and mouse pituitary. Ann. N. Y. Acad. Sci. 1040, 84–88 (2005).
Ho, Y. et al. Single-cell transcriptomic analysis of adult mouse pituitary reveals sexual dimorphism and physiologic demand-induced cellular plasticity. Protein Cell 11, 565–583 (2020).
Makri, A. & Lodish, M. Gigantism and Acromegaly. In (Brenda Kohn (ed.)) Contemporary Endocrinology 121–139 (Springer, Humana Press, 2019).
Wettschureck, N. & Offermanns, S. Mammalian G proteins andtheir cell type specific functions. Physiol. Rev. 85, 1159–1204 (2005).
Mear, Y., Enjalbert, A. & Thirion, S. GHS-R1a constitutive activity and its physiological relevance. Front. Neurosci. 7, 87 (2013).
Davenport, A. P. et al. International union of pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev. 57, 541–546 (2005).
Vaudry, D. et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61, 283–357 (2009).
Harmar, A. J. et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1. Br. J. Pharm. 166, 4–17 (2012).
Spongier, D. et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365, 170–175 (1993).
Pantel, J. et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 116, 760–768 (2006).
Parma, J. et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365, 649–651 (1993).
Shenker, A. et al. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365, 652–654 (1993).
Asa, S. L. & Ezzat, S. The pathogenesis of pituitary tumors. Annu. Rev. Pathol. Mech. Dis. 4, 97–126 (2009).
Mantovani, G. et al. Parental origin of Gsα mutations in the McCune-Albright syndrome and in isolated endocrine tumors. J. Clin. Endocrinol. Metab. 89, 3007–3009 (2004).
Solloso, A. et al. GHRH proliferative action on somatotrophs is cell-type specific and dependent on Pit-1/GHF-1 expression. J. Cell. Physiol. 215, 140–150 (2008).
Hayes, J. S., Brunton, L. L., Brown, J. H., Reese, J. B. & Mayer, S. E. Hormonally specific expression of cardiac protein kinase activity. Proc. Natl Acad. Sci. USA 76, 1570–1574 (1979).
Brunton, L. L., Hayes, J. S. & Mayer, S. E. Hormonally specific phosphorylation of cardiac troponin I and activation of glycogen phosphorylase. Nature 280, 78–80 (1979).
Guan, X. M., Kobilka, T. S. & Kobilka, B. K. Enhancement of membrane insertion and function in a type IIIb membrane protein following introduction of a cleavable signal peptide. J. Biol. Chem. 267, 21995–21998 (1992).
Schrage, R. et al. The experimental power of FR900359 to study Gq-regulated biological processes. Nat. Commun. 6, 10156 (2015).
Devost, D. et al. Conformational profiling of the AT1 angiotensin II receptor reflects biased agonism, G protein coupling, and cellular context. J. Biol. Chem. 292, 5443–5456 (2017).
Miller, T. L., Godfrey, P. A., DeAlmeida, V. I. & Mayo, K. E. The rat growth hormone-releasing hormone receptor gene: structure, regulation, and generation of receptor isoforms with different signaling properties1. Endocrinology 140, 4152–4165 (1999).
